Undergoing Changes

You may have noticed that the CED Website and member-area are undergoing changes. We're working to better serve you. Our blog will remain here, covering member news and stories from the Triangle.

Monday, January 21, 2013

LipoScience refiles IPO, aims for up to $75 million

CED Member LipoScience is seeking between $65 and $75 million through an initial public offering, based on a filing with the SEC earlier this month.

This is the second time the firm has pursued an IPO option. The first was in a June 2011 filing.

If the IPO goes through as planned, LipoScience would trade on the Nasdaq under the symbol LPDX.

In the latest filing on Jan. 10, 2013, LipoScience set a target price between $13 and $15 a share for a total of five million shares.

The IPO arrives soon after the firm received FDA approval for a new test through its Vantera system this past September. LipoScience received FDA 510(k) clearance on its Vantera Clinical Analyzer.

LipoScience's venture capital investors include Durham-based CED Member Pappas Ventures.

No comments:

Post a Comment